MoonLake Immunotherapeutics (MLTX) Current Leases (2022 - 2026)

MoonLake Immunotherapeutics' Current Leases history runs 5 years deep, the most recent figure standing at $920000.0 for Q1 2026.

• On a quarterly basis, Current Leases fell 35.75% year-over-year to $920000.0 in Q1 2026; TTM through Mar 2026 was $920000.0, a 35.75% decrease from a year earlier, with the FY2025 full-year figure at $1.2 million, down 10.06% from the prior year.
• Current Leases declined to $920000.0 in Q1 2026 per MLTX's latest filing, from $1.2 million in the prior quarter.
• Across five years, Current Leases topped out at $1.5 million in Q2 2025 and bottomed at $153629.0 in Q4 2022.
• The 5-year median for Current Leases is $1.3 million (2024), against an average of $992805.9.
• Across the five-year window, Current Leases jumped 824.21% in 2024 and plunged 35.75% in 2026, its largest moves.
• Year by year, Current Leases stood at $153629.0 in 2022, then jumped by 679.72% to $1.2 million in 2023, then gained by 14.54% to $1.4 million in 2024, then retreated by 10.06% to $1.2 million in 2025, then retreated by 25.45% to $920000.0 in 2026.
• Per Business Quant, the three latest MLTX Current Leases figures stand at $920000.0 (Q1 2026), $1.2 million (Q4 2025), and $1.5 million (Q3 2025).